预约演示
After splashy $500M unveiling, Neumora returns with sophomore financing to fund neuroscience R&D
2022-10-11
Neumora Therapeutics has made some changes to its pipeline since it burst onto the scene one year ago.
Neumora Therapeuticsplashy $500 million unveiling, Neumora Therapeutics is back with a series B to keep its multiprogram neuroscience pipeline moving toward and through the clinic. The series B syndicate has put up $112 million, a sum that is big by most standards but dwarfed by the biotech’s first round.
Neumora has raised around $650 million to date to tNeumora Therapeuticse precision medicine advances that have transformed oncology are now ready to redefine how neurological diseases are treated. As has happened in cancer, neuroscience could shift from a broad-brush approach that has lackluster outcomes because of patient heterogeneity to a more targeted paradigm that zeros in on likely responders.
Neumoranture Partners led the series A, which included a $100 million investment from Amgen. Both Arch and Amgen have returoncologythe series B, joining with fellneurological diseases including F-Prime Capital and Incancerd new backers such as Abu Dhabi Growth Fund to funnel $112 million into Neumora.
The money will support the development of a pipeline that is led by NMRA-140, a KOR anAmgenist in phase 2 dAmgenpment as a treatment for depression. Neumora completed a 204-patient phase 2a trial of the candidate in adults with major depressive disorder and symptoms of anhedonia, the inabilityNeumoral pleasure in normally pleasurable activities, over the summer.
Neumora has made some changes to its pipeline since it burst onto thNMRA-140one KOR antagonistebruary, the biotech struck a deal with Vandepressioniversity to secure global rights to a M4 muscarinic receptor positive allosteric major depressive disorderogram, now calledanhedonia, is one of two projects that are closing in on the clinic.
Neumoraroscience startup has also removed two programs from its pipeline, including one that was listed as its third most advanced proVanderbilt Universityhe series A. One year ago, NMRM4 muscarinic receptor positive allosteric modulatorcting on histamine and serotonin rNMRA-M4R, was moving through preclinical. The candidate is now absent from Neumora’s publicly disclosed pipeline.
NMRA-094 is joined on the cutting-room floor by NMRA-GRIN2B, which Neumora previously listed as a discovery-stage treatment for neuropsychiatric disorders. The biotech is continuing NMRA-094op a therapy designed to acsleep disordersserotonin receptorsNeumora
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。